Peer-reviewed veterinary case report
Antibody response to parvovirus vaccine in dogs with adrenal disease
By Bergmann, Michèle et al.·Published in Vaccines·2020·Clinic of Small Animal Medicine, LMU Munich, 80539 Munich, Germany, Germany·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Antibody Response to Canine Parvovirus Vaccination in Dogs with Hyperadrenocorticism Treated with Trilostane
- Species:
- dog
Plain-English summary
A group of dogs with hyperadrenocorticism (HAC), a condition that affects hormone levels, were vaccinated against canine parvovirus to see how well they responded compared to healthy dogs. All the dogs with HAC had some antibodies before vaccination, but they did not show a significant increase in antibody levels after the vaccine, while some healthy dogs did. Mild side effects were noted in over half of the dogs with HAC, but overall, their immune response to the vaccine appeared similar to that of healthy dogs. This suggests that dogs with HAC can still be vaccinated effectively.
People also search for: dog parvovirus vaccination response · hyperadrenocorticism in dogs · vaccine side effects in dogs
Abstract
It is unknown how dogs with hyperadrenocorticism (HAC) respond to vaccination. This study measured antibodies against canine parvovirus (CPV) in dogs with HAC treated with trilostane before and after CPV vaccination, and compared the immune response to that from healthy dogs. Eleven dogs with HAC, and healthy age-matched control dogs (n = 31) received a modified-live CPV vaccine. Antibodies were determined on days 0, 7, and 28 by hemagglutination inhibition. Univariate analysis was used to compare the immune response of dogs with HAC and healthy dogs. Pre-vaccination antibodies (≥10) were detected in 100% of dogs with HAC (11/11; 95% CI: 70.0–100) and in 93.5% of healthy dogs (29/31; 95% CI: 78.3–99.2). No ≥4-fold increase in antibody titer was observed in dogs with HAC while in 22.6% of healthy dogs, a ≥4-fold titer increase was observed (7/31; 95% CI: 11.1–40.1). Mild vaccine-associated adverse events (VAAEs) were detected in 54.5% of dogs with HAC (6/11; 95% CI: 28.0–78.8) and in 29.0% of healthy dogs (9/31; 95% CI: 15.9–46.8). There was neither a significant difference in presence of pre-vaccination antibodies (p = 1.000), or response to vaccination (p = 0.161), nor in the occurrence of VAAEs (p = 0.158). Immune function of dogs with HAC treated with trilostane seems comparable to that of healthy dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.3390/vaccines8030547